Holland Nina T, Pfleger Laura, Berger Eileen, Ho Alan, Bastaki Maria
Environmental Health Sciences, School of Public Health, University of California, 317 Warren Hall, Berkeley 94720-7360, USA.
Toxicol Appl Pharmacol. 2005 Aug 7;206(2):261-8. doi: 10.1016/j.taap.2004.10.024.
Biomarker studies require processing and storage of numerous biological samples with the goals of obtaining a large amount of information and minimizing future research costs. An efficient study design includes provisions for processing of the original samples, such as cryopreservation, DNA isolation, and preparation of specimens for exposure assessment. Use of standard, two-dimensional and nanobarcodes and customized electronic databases assure efficient management of large sample collections and tracking results of data analyses. Standard operating procedures and quality control plans help to protect sample quality and to assure validity of the biomarker data. Specific state, federal and international regulations are in place regarding research with human samples, governing areas including custody, safety of handling, and transport of human samples. Appropriate informed consent must be obtained from the study subjects prior to sample collection and confidentiality of results maintained. Finally, examples of three biorepositories of different scale (European Cancer Study, National Cancer Institute and School of Public Health Biorepository, University of California, Berkeley) are used to illustrate challenges faced by investigators and the ways to overcome them. New software and biorepository technologies are being developed by many companies that will help to bring biological banking to a new level required by molecular epidemiology of the 21st century.
生物标志物研究需要对大量生物样本进行处理和存储,目的是获取大量信息并尽量降低未来的研究成本。高效的研究设计包括对原始样本进行处理的相关规定,例如冷冻保存、DNA提取以及为暴露评估准备样本。使用标准的二维和纳米条形码以及定制的电子数据库可确保对大量样本集进行高效管理并跟踪数据分析结果。标准操作程序和质量控制计划有助于保护样本质量并确保生物标志物数据的有效性。对于涉及人类样本的研究,有特定的州、联邦和国际法规,涵盖人类样本的保管、处理安全和运输等领域。在采集样本之前,必须获得研究对象的适当知情同意,并对结果保密。最后,以三个不同规模的生物样本库(欧洲癌症研究、美国国立癌症研究所和加利福尼亚大学伯克利分校公共卫生学院生物样本库)为例,说明研究人员面临的挑战以及克服这些挑战的方法。许多公司正在开发新的软件和生物样本库技术,这将有助于使生物样本库达到21世纪分子流行病学所要求的新水平。